Vimarsana
Biggest News Aggregation in the World

Page 32 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - Vimarsana News

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer

Published: March 17, 2022

NEWTON, Mass. - Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that results from the Phase 3 SIENDO study will be presented at... | March 17, 2022

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomRegion FlamandeSouth KoreaSarah ConnorsElhan WebbSelective Inhibitor Of Nuclear ExportSociety For Gynecologic OncologyKaryopharm Therapeutics IncLeuven University HospitalsEuropean Society Of Medical OncologyDrug AdministrationExchange CommissionCorporate CommunicationsKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentMedical OncologyVirtual PlenaryGynecologic OncologyScientific PlenarySelective InhibitorNuclear ExportMedical InformationPrivate Securities Litigation Reform ActRisk Factor
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - Vimarsana News

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer

Published: March 16, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaRegion FlamandeSelective Inhibitor Of Nuclear ExportEuropean Society Of Medical OncologyEuropean Society Of Medical Oncology Virtual PlenaryInternational Agency For Research On CancerKaryopharm Selective Inhibitor Of Nuclear ExportAmerican Cancer SocietyInformation DepartmentKaryopharm Therapeutics IncSociety For Gynecologic OncologyLeuven University HospitalsCompany To Host Investor Conference Call OnWorld Health OrganizationDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionNation Cancer InstituteStudy ResultsEuropean SocietyMedical OncologyVirtual Plenary
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - Vimarsana News

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer

Published: March 16, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaRegion FlamandeSelective Inhibitor Of Nuclear ExportEuropean Society Of Medical OncologyEuropean Society Of Medical Oncology Virtual PlenaryInternational Agency For Research On CancerKaryopharm Selective Inhibitor Of Nuclear ExportAmerican Cancer SocietyInformation DepartmentKaryopharm Therapeutics IncSociety For Gynecologic OncologyLeuven University HospitalsCompany To Host Investor Conference Call OnWorld Health OrganizationDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionNation Cancer InstituteStudy ResultsEuropean SocietyMedical OncologyVirtual Plenary
Karyopharm Names New Head of I - GuruFocus.com - Vimarsana News

Karyopharm Names New Head of I - GuruFocus.com

Published: March 15, 2022

GuruFocus Article or News written by PRNewswire and the topic is about:

Source: gurufocus.com
Related Topics:
United StatesUnited KingdomRichard PaulsonLombard OdierElhan WebbSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncBogazici UniversityDrug AdministrationUniversity Of Southern CaliforniaPrnewswire Karyopharm Therapeutics IncExchange CommissionMasters In Business AdministrationEuropean UnionRadius HealthBusiness DevelopmentRubius TherapeuticsSenior Vice PresidentInvestor RelationsWebb Brings MoreInvestment AnalysisPortfolio ManagementBiotechnology FieldsChief Executive OfficerVice President
Karyopharm Names New Head of Investor Relations - Vimarsana News

Karyopharm Names New Head of Investor Relations

Published: March 14, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomRichard PaulsonLombard OdierElhan WebbSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncBogazici UniversityDrug AdministrationUniversity Of Southern CaliforniaPrnewswire Karyopharm Therapeutics IncExchange CommissionMasters In Business AdministrationEuropean UnionRadius HealthBusiness DevelopmentRubius TherapeuticsSenior Vice PresidentInvestor RelationsWebb Brings MoreInvestment AnalysisPortfolio ManagementBiotechnology FieldsChief Executive OfficerVice President